Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D Furberg

Showing results (51-60 of 205) with videos related to

Pageof 21
Sort By:
Circulation|February 1, 1995
Clinical trial Data and Safety Monitoring Boards. The search for a constitutionP W Armstrong, C D Furberg
Anesthesia and Analgesia|April 1, 1989
Nimodipine and the "no-reflow phenomenon"--experimental triumph, clinical failure?D S Prough, C D Furberg
Herz|December 1, 1995
Should calcium antagonists be first line drugs in hypertension?C D Furberg, B M Psaty
Archives of Internal Medicine|November 13, 1995
Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con sideC D Furberg, B M Psaty
Current Opinion in Nephrology and Hypertension|March 1, 1994
Hypertensive cardiovascular disease and the treatment of hypertension in the elderlyK A Pearce, C D Furberg
American Journal of Hypertension|May 23, 2000
Comparisons in a competitive world: when is one drug superior to another?M A Weber, C D Furberg
BMJ (Clinical Research Ed.)|September 3, 1999
British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunityB M Psaty, C D Furberg
The New England Journal of Medicine|October 7, 1982
Community hospitals in clinical trialsL M Friedman, C D Furberg
The American Journal of Medicine|June 22, 1984
Effect of long-term prophylactic treatment on survival after myocardial infarctionC D Furberg, G S May
Lancet (London, England)|February 4, 1995
Reversing risk in coronary diseaseR P Byington, C D Furberg
Pageof 21

Showing results (51-60 of 205) with videos related to

Sort By:
Pageof 21
Circulation|February 1, 1995
Clinical trial Data and Safety Monitoring Boards. The search for a constitutionP W Armstrong, C D Furberg
Anesthesia and Analgesia|April 1, 1989
Nimodipine and the "no-reflow phenomenon"--experimental triumph, clinical failure?D S Prough, C D Furberg
Herz|December 1, 1995
Should calcium antagonists be first line drugs in hypertension?C D Furberg, B M Psaty
Archives of Internal Medicine|November 13, 1995
Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con sideC D Furberg, B M Psaty
Current Opinion in Nephrology and Hypertension|March 1, 1994
Hypertensive cardiovascular disease and the treatment of hypertension in the elderlyK A Pearce, C D Furberg
American Journal of Hypertension|May 23, 2000
Comparisons in a competitive world: when is one drug superior to another?M A Weber, C D Furberg
BMJ (Clinical Research Ed.)|September 3, 1999
British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunityB M Psaty, C D Furberg
The New England Journal of Medicine|October 7, 1982
Community hospitals in clinical trialsL M Friedman, C D Furberg
The American Journal of Medicine|June 22, 1984
Effect of long-term prophylactic treatment on survival after myocardial infarctionC D Furberg, G S May
Lancet (London, England)|February 4, 1995
Reversing risk in coronary diseaseR P Byington, C D Furberg
Pageof 21